NCT07060066Recruiting
Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia
Source: ClinicalTrials.gov · Last updated 5 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to provide an effective repetitive transcranial magnetic stimulation (rTMS) treatment for depressive symptoms in patients with schizophrenia. Schizophrenia patients with depressive symptoms will be exposed to rTMS to improve their symptoms.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 1 Jul 2025
- Start date
- 23 Oct 2025
- Primary completion date
- 1 Jun 2030
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Diseases
- Schizophrenia
- NCT number
- NCT07060066
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 23 Oct 2025 to the primary completion date, 1 Jun 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Significant alcohol or other drug use other than nicotine or marijuana dependence.
- Inability to refrain from using alcohol and/or marijuana 24 hours or more prior to experiments.
Other illness
- Any major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but are not limited to: stroke, repeated seizure, history of significant head trauma with cognitive sequela, CNS infection or tumor, other significant brain neurological conditions.
- For MRI, inability to participate in the MRI scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips or other implanted metal parts) or declining to get in the scanner.
Other
- Inability to sign informed consent.
- Pregnancy, as classified by a woman of child-bearing potential who is not using a contraceptive and has missed a menstrual period; or by self-report; or by positive urine pregnancy test.
- Failed TMS safety questionnaire.
Who the study is looking for
- Male and female ages between ages 18-60 years.
- Ability to give written informed consent (age 18 or above).
- Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above 10.
- Score of Calgary depression scale for schizophrenia (CDSS) ≥ 3.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Texas Health Science Center at Houston Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.